Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions

Cheikh, Jean El; Otrock, Zaher K.; Qannus, Abd Assalam; Kharfan‐Dabaja, Mohamed A.; Bazarbachi, Ali

doi:10.1016/j.clml.2016.01.005

Cited by 9 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,8,16 In the current study, we retrospectively reported on 27 patients who received sorafenib after HSCT as a maintenance therapy. As previously reported in preliminary data from our group, 17,18 the results presented herein confirm the efficacy of this strategy, with patients experiencing long-term disease control with concomitant manageable and reversible toxicities.…”

Section: Discussionsupporting

confidence: 88%

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia

Battipaglia

Ruggeri

Massoud

et al. 2017

Cancer

Self Cite

104

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia

Battipaglia

Ruggeri

Massoud

et al. 2017

Cancer

Self Cite

104

View full text Add to dashboard Cite

show abstract

“…Allo-HSCT is personalized: an individualized approach could also include personalized conditioning according to pharmacogenetic and pharmacokinetic data and different risk-stratified post-transplant procedures [ 10 11 ]. The personalized management of the underlying disease is, to date, molecular-driven, and MRD monitoring [ 12 ] predicts relapse and permits to act with cellular [ 13 ], targeted [ 14 ] or manipulated cellular therapies.…”

Section: What Is the Role Of Allogeneic Hsct In The Era Of Targeted Tmentioning

confidence: 99%

The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era

et al. 2018

View full text Add to dashboard Cite

“…The paradigm of maintenance therapy after allo-HCT is becoming more popular. 69 For instance, in patients with CML or Ph+ ALL, treatment with inhibitors of the BCR-ABL tyrosine kinase is widely used as prophylaxis or as therapy for minimal residual disease. 70,71 The incorporation of sorafenib in the maintenance setting is supported by the observation that there appears to be an antileukemia synergism between sorafenib and alloreactive donor cells.…”

Section: Sorafenib As Maintenance Therapy After Allo-hctmentioning

confidence: 99%

Inhibition of FLT3 in AML: a focus on sorafenib

Antar

Otrock

El‐Cheikh

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

FMS-like tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in AML. FLT3 is mutated in ~30% of patients with AML, either by internal tandem duplications (FLT3-ITD) of the juxta-membrane domain or by a point mutation, usually involving the tyrosine kinase domain. Several FLT3 tyrosine kinase inhibitors are being evaluated in multiple studies aiming at improving outcomes. The most widely used is sorafenib, a potent multikinase inhibitor approved for hepatocellular carcinoma and renal cell carcinoma. Sorafenib monotherapy or in combination with conventional chemotherapy, has been evaluated in various settings in AML, including front-line, relapsed or refractory disease including post-allograft failures and, more recently, as post-transplant maintenance therapy. Encouraging data have emerged with several other agents like lestaurtinib, midostaurin, crenolanib, gilteritinib and quizartinib. Although transient responses to FLT3 inhibitors are often observed in case of disease relapse, the most promising approach is the use of FLT3 inhibitors either in combination with induction chemotherapy or as consolidation/maintenance therapy after allogeneic hematopoietic cell transplantation. In this review, we summarize the clinical data on sorafenib and other FLT3 inhibitors in AML.

show abstract

Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions

Cited by 9 publications

References 27 publications

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia

The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era

Inhibition of FLT3 in AML: a focus on sorafenib

Contact Info

Product

Resources

About